Barclays Maintains Equal-Weight on PTC Therapeutics, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has maintained an Equal-Weight rating on PTC Therapeutics (NASDAQ:PTCT) but lowered the price target from $26 to $25.
October 27, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on PTC Therapeutics but lowered the price target from $26 to $25.
The lowering of the price target by Barclays indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on PTC Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100